跳至主要内容
临床试验/ACTRN12623000909628
ACTRN12623000909628尚未招募Unknown

A 12-month follow-up to determine maintenance of lifestyle change and selected clinical outcomes in the South Australian MedWalk study participants.

niversity of South Australia0 个研究点目标入组 74 人开始时间: 2023年8月23日最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
74

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
61 Years 至 91 Years(—)
性别
All

入选标准

  • Aged 61-91 years
  • Completed at least part of their MedWalk 12 month visit (South Australian cohort).
  • Willing and able to complete the follow-up study.

排除标准

  • Death or severe disability that has occured between completion of the MedWalk study and the follow-up study commencement.

研究者

发起方
niversity of South Australia

相似试验

尚未招募
不适用
A 12-month, non-interventional, observational multinational study to evaluate effectiveness, tolerability, and quality of life of brivaracetam adjunctive therapy in earlier treatment lines in adult patients with history of partial-onset seizures in daily clinical practice.
DRKS00025524Parexel International (IRL) Limited (Clinical Research Organisation)600
撤回
不适用
A 12-month Longitudinal, Prospective, Observational, Natural History Study of Patients with Sanfilippo Syndrome Type A (MPS IIIA)MPS IIIASanfilippo syndrome Type A1002742410057167
NL-OMON32977Shire Human Genetic Therapies5
尚未招募
不适用
A observational study assessing the real world data on inititating treatment of Toujeo after oral antidiabetic drug failure in insulin-naive patients with Type 2 Diabetes Mellitus patients.
CTRI/2018/02/012158Sanofi India Limited
进行中(未招募)
不适用
One year follow-up of patients treated in Study 1206.5, a 12 week double-blind, randomised, placebo-controlled, modified dose-escalation trial to investigate safety, efficacy, and pharmacokinetics of BIRT 2584XX tablets at doses of 100,300 and 500 mg administered once daily in patients with moderate to severe psoriasis with a 12 week treatment extension for PASI 50 responders.
EUCTR2007-004328-18-GBBoehringer Ingelheim Limited
招募中
1 期
A long term follow up study of ATX-101 given by intravenous infusion once every week in patients with advanced solid tumours.Advanced Solid TumorsCancer - Any cancer
ACTRN12618001112257Therapim Pty Ltd36